Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Histologically confirmed non-Hodgkin's lymphoma, including 1 of the following:~  * Follicular grade 1 or 2~ * Small lymphocytic~ * Marginal zone (nodal)~ * Marginal zone (splenic)~ * Mucosa-associated lymphoid tissue (MALT)~* Stage III or IV disease~* Must meet the following criteria for low tumor burden:~  * No nodal or extranodal mass at least 7 cm~ * Less than 3 nodal masses greater than 3 cm in diameter~ * No systemic symptoms or B symptoms~ * No splenomegaly greater than 16 cm by a computed tomography (CT) scan~ * No evidence of risk of compression of a vital organ (i.e., ureteral or epidural)~ * No leukemic phase with greater than 5,000/mm\^3 circulating lymphocytes~ * No cytopenias, defined as any of the following:~    * Platelet count less than 100,000/mm\^3~   * Hemoglobin less than 10 g/dL~   * Absolute neutrophil count less than 1,500/mm\^3~* At least 1 objective measurable disease parameter~  * Abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by CT scan or other appropriate imaging~* Age: 18 and over~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Must meet the following criteria for labs:~  * Hematopoietic~    * Absolute neutrophil count at least 1,500/mm\^3\*~   * Hemoglobin at least 10 g/dL\*~   * Platelet count at least 100,000/mm\^3\*~   * NOTE: \*Without growth factor and/or transfusion support~ * Hepatic~    * Bilirubin no greater than 2 times upper limit of normal (ULN) OR direct bilirubin normal for patients with Gilbert's Syndrome~   * The aspartate transaminase (AST) and alanine transaminase (ALT) ratio (AST/ALT) no greater than 5 times ULN~   * Hepatitis B surface antigen negative~ * Renal~    * Creatinine no greater than 2 times ULN~EXCLUSION CRITERIA:~* Evidence of transformation to a large cell histology~* Pregnant or nursing. Fertile patients must use effective contraception~* HIV positive~* Uncontrolled active infection~* Other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* Prior immunotherapy for lymphoma~* Prior chemotherapy for lymphoma~* Concurrent chemotherapy~* Prior radiotherapy for lymphoma~* Concurrent radiotherapy~* Concurrent radioimmunotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Rituximab Retreatment (Type: ACTIVE_COMPARATOR): Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
- Arm B: Rituximab Scheduled (Type: EXPERIMENTAL): Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).